Trial Profile
A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Fobrepodacin (Primary)
- Indications Nontuberculous mycobacterium infections; Tuberculosis
- Focus Adverse reactions; First in man
- Sponsors Spero Therapeutics
- 07 Sep 2021 Results evaluating the safety, tolerability, and pharmacokinetics (PK) of SPR720/SPR719 in a single ascending dose (SAD) /multiple ascending dose (MAD) in healthy volunteers published in the Antimicrobial Agents and Chemotherapy
- 25 Oct 2020 Results presented at the IDWeek 2020
- 16 Oct 2020 According to a Spero Therapeutics media release, results from this study will be presented in a poster presentation at the Infectious Disease Society of America (IDSA) IDWeek 2020 taking place virtually from 21st to 25th Oct 2020.